Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ABPH, buy this now before the close, or watch it go BIGGLY tomorrow imo
LOL, I think u will do VERY VERY well.
Well im in @.014 thoughts of any more of a run or did I just get screwed.lol
HUGE gap and run tomorrow. And no shares left.
i got my tickets @ .0016 and .002
"ABPH - LISTEN CLOSE. All MM's only own 2.163 million shares in TOTAL. This thing is ULTRA THIN..".
It will hit scanners tonight , watch out tomorrow!!
Fasten your seatbells!
Boardmarks are rising, spread the word!
.015
My feeling says ? .
Something big cooking here !!!!!
DO ur dd, fascinating tech and rumor of european approval. AND no shares there. MONSTER.
why ? and how can you be sure ?
ABPH has dollar potential. Fasten ur seatbelts. No shares there, extremely thin.
.014!!OOPS, .0145!! .015 on the ask now.
Wow, I was going to buy this at .0065!!! Congrats to you who did the DD on this! Looks great!
Yup, this is a dollar stock.
Ollin:
To see that info, go to www.otcbb.com,
then choose ABPH (of course), click "Charts" & then once that comes up select "Monthly Share Volume" on the right & it will bring u to that page. It's real good for DD & such. It now says 2.163 Mill owned by the MM's. But that still means the float must be THINNNNNN. And the MM's probably picked up those shares today from people dumping... DON'T SELL FOLKS! We could see a dollar soon for real... [I know they'll still be selling] Lol
Yes, incredible tech. ANd with approval, it will trade above a buck pronto. HUGE find. Amazing.
This gonna be a $ stock !!!!!
if this rumor about European approval is true, this is a 1 $ stock pronto with such a low float.
BioScanIR® The most advanced infrared sensors used in Space are now part of the most advanced biomedical infrared imaging system on the planet - the BioScanIR® System:
Detects dynamic changes in blood perfusion in tissue and organs by sensing minute changes in thermal photon flux
Completely non-invasive—no contrast agents, no ionizing radiation used
Fast results—scans in 20 seconds and data reports available in minutes
Low cost—up to 80% less than other functional imaging modalities FDA-Cleared, UL-Certified and CE-Marked
The BioScanIR System is an infrared-based functional imaging system that detects minute changes in blood perfusion through the capture of passively-emitted infrared radiation that is produced by tissue. Through the analysis of this captured radiation, the system can help physicians and researchers differentiate between normal and abnormal tissue. In this fashion, the BioScanIR System can detect diseases and conditions that affect the perfusion or reperfusion of blood in tissue and organs.
The BioScanIR System is totally non-invasive, and does not contact the patient in any way. It uses no radiation, and requires no contrast agent. It can be used by non-imaging specialists, and can be used in a non-sterile, office environment. The BioScanIR System has multiple clinical applications including:
Monitoring response to cancer drug therapy.
Monitoring intervention in diabetic driven peripheral vascular disease.
Identifying perforator vessels during pre-surgical planning, and assessing post-operative perfusion of pedicle flaps following reconstructive surgery (i.e. of the breast).
Mapping of functional cortex in patients undergoing tumor surgery.
Determining cardiac bypass graft patency and perfusion of the myocardium in cardiac surgery.
The BioScanIR System can be used adjunctively with more expensive modalities such as CT, MRI, functional MRI and PET imaging.
To learn more about specific clinical use, visit our Applications Section
Yep, run baby run!
008 ! weeeeeeeeeeeeeeeeeee
Where did You get this info from? Sounds great!
Well I DID find this out... ALL of the MM's together only own 1.484 Million shares of this so the float must be REALLLLLLY THIN.
What's the float Ash? Been trying 2 get a VERY small order to go through ON THE ASK for 15+ minutes... Can't find it on pinksheets, seems like it must be kinda thin. Wondering if the iBox O/S is correct...
Thanks. I hope for news soon.
cw
ABPH-this srock was traded at .25-1$(2006-2007).HUGE POTENTIAL HERE.
Hey, thx. I hope so also! I need 2 cents yo get out.
cw
hi
it is very annoying, that the chart here is not working.
According to pinksheets.com the b/a was 0.006 x 0.0065
Looking good for tomorrow!
Hey guys, what was bxa at closing? IH show 0.0012 as always. It's sucks. MAtt, what's going on?
cw
Yes, good day for abph. Think tomorrow will be better ;)
More and more eyes are following this one. If there is more volume a lot people will jump in!
New report online since yesterday. Costs $115
http://reports.finance.yahoo.com/w0?r=41674567:1
"...intelligence for investors, competitors and partners. Save both time and money by instantly accessing public company data that can be difficult to source independently."
May be interesting for new partners who want to finish the studies on DIRI.
Thanks for the insight ollinbg
ABPH-i like that co.let me tell u somthing:
in the past i bought CTIC, AT .06. sold it at .01. after 2 month i saw it at 1.5$
i don't want to miss it again, i am realy thinking ABPH-could be a 1$ stock, someday.
this srock was traded at .25-1$(2006-2007).
Interesting - study results:
There was a presentation of study results with the DIRI from ABPH in Juli 2009. You can find it, if You type in 1801 at "Poster Number" on this page: http://www.aad.org/forms/ePosterPresentations/Default.aspx
The Presentation-Link:
http://www.aad.org/meetings/summer/abstracts/_doc/Melanoma%20and%20Pigmented%20Lesions.pdf
The study was sponsored by ABPH! (see at the end)
Melanoma and Pigmented Lesions
P1801
Dynamic infrared imaging (DIRI®) of pigmented lesions of the skin: A pilot study of a thermal and vascular imaging modality to distinguish malignant from benign lesions
Caroline C. Kim, MD, Pigmented Lesion Clinic and Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Erika Summers, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; John Mullen, MD, Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Maria Laura Gomez, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dynamic Infrared Imaging (DIRI) is a noninvasive imaging technique that passively records natural Infrared Radiation (IR) emitted from living tissues that has been shown to be able to detect minute temperature changes (0.006 degrees Celsius) and vasomotor changes to a depth of ~ 200 micrometers. We hypothesized that DIRI could detect such tissue surface changes induced by a cutaneous malignancy as compared to the surrounding normal skin. A pilot study was conducted examining twenty patients from our Cutaneous Oncology and Pigmented Lesion Clinics with suspicious skin lesions that warranted biopsy to assess the utility of DIRI in skin lesions. Suspicious skin lesions were scanned with DIRI then biopsied, and DIRI results were compared to the histologic diagnoses. The investigators were blinded throughout the study and all scans were analyzed by Advanced BioPhotonics, Inc. A total of 24 skin lesions were analyzed including 4 melanomas (1 invasive, 1 melanoma in-situ, 2 metastatic), 1 squamous cell in-situ (SCCIS), and 19 benign skin lesions. DIRI correctly identified 4 out of 4 melanomas as malignant, and 15 out of 19 benign lesions as benign, while there were 4 false positive results (benign and atypical nevi) and one false negative result (SCCIS). For all cancers, it had a diagnostic sensitivity of 80 % (95% confidence interval [CI]: 28-100%), and a specificity of 78.9% (95% CI: 54-94%). For melanoma detection, however, it had a sensitivity of 100% (95% CI: 40-100%) and specificity of 80% (95% CI: 56-94%). It is notable that DIRI correctly identified the melanoma in-situ as having an altered thermal and tissue perfusion pattern rendering the malignant interpretation, perhaps suggesting that underlying vasomotor changes are already evident at this early stage of disease. In contrast, other skin tumors such as SCCIS may not have such changes. Scanning technique is being reevaluated to assess the false positive scans, given the extreme sensitivity of the instrument to temperature shifts. In summary, this is the first study using a thermal and vascular imaging modality in the investigation of cutaneous melanoma. The results, though preliminary and from a small sample, warrant further investigation with this novel imaging technique in the screening of pigmented skin lesions for cutaneous melanoma.
Commercial Support: 40% of research costs sponsored by Advanced BioPhotonics, Inc.
0065, painted close for 100sh....
Can somebody post closing sp?
Thx.
cw
ABPH status: operating (according to this website)
http://www.linkedin.com/companies/advanced-biophotonics-inc.
When You google this:
"advanced biophotonics technologies" ltd bohemia
You get this result:
Early Detection of Flap Failure Using a New Thermographic Device ...
-
from X Tenorio - 2009
The BioScanIR System (Advanced BioPhotonics Technologies Ltd., Bohemia, NY) is a novel infrared-based imaging setup that can detect minute changes in blood ...
linkinghub.elsevier.com/retrieve/pii/S0022480408001856
Is there a ltd-company called Advanced BioPhotonics Technologies Ltd. a hidden subsidary of ABPH?!
A report about ABPH from January this year.
http://bharatbookcompanyprofile.blogetery.com/2010/01/16/advanced-biophotonics-inc-strategic-analysis-review/
Quite expensive ;)
Seems like we have some new strong hands in ABPH. Holding good. Wait for a close above 0.005
Welcome aboard br_2, and GLTY!
It trades nice I like it . To tell you the truth I love playing with empty shell Because once they run , they run like a wild dog and you cant chase them lol
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
840
|
Created
|
03/09/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/h?s=ABPH.PK
BioScanIR® The most advanced infrared sensors used in Space are now part of the most advanced biomedical infrared imaging system on the planet - the BioScanIR® System:
Detects dynamic changes in blood perfusion in tissue and organs by sensing minute changes in thermal photon flux
Completely non-invasive—no contrast agents, no ionizing radiation used
Fast results—scans in 20 seconds and data reports available in minutes
Low cost—up to 80% less than other functional imaging modalities FDA-Cleared, UL-Certified and CE-Marked
The BioScanIR System is an infrared-based functional imaging system that detects minute changes in blood perfusion through the capture of passively-emitted infrared radiation that is produced by tissue. Through the analysis of this captured radiation, the system can help physicians and researchers differentiate between normal and abnormal tissue. In this fashion, the BioScanIR System can detect diseases and conditions that affect the perfusion or reperfusion of blood in tissue and organs.
The BioScanIR System is totally non-invasive, and does not contact the patient in any way. It uses no radiation, and requires no contrast agent. It can be used by non-imaging specialists, and can be used in a non-sterile, office environment. The BioScanIR System has multiple clinical applications including:
Monitoring response to cancer drug therapy.
Monitoring intervention in diabetic driven peripheral vascular disease.
Identifying perforator vessels during pre-surgical planning, and assessing post-operative perfusion of pedicle flaps following reconstructive surgery (i.e. of the breast).
Mapping of functional cortex in patients undergoing tumor surgery.
Determining cardiac bypass graft patency and perfusion of the myocardium in cardiac surgery.
The BioScanIR System can be used adjunctively with more expensive modalities such as CT, MRI, functional MRI and PET imaging.
To learn more about specific clinical use, visit our Applications Section
STAR WARS MEDICINE, ON EARTH
Venture capitalists and corporate
investors ‘sense’ OmniCorder
Technologies’ star potential at
recent Medtech Insight conference.
by Ronald C. Trahan
A PREVIEW OF EARLY-STAGE
MEDICAL TECHNOLOGY COMPANIES
The latest Filings and News:
December 17th 2007..... Big News.... Please Read
http://biz.yahoo.com/bw/071217/20071217006052.html?.v=1
MISC NEWS:
Frost & Sullivan's 2005 Medical Imaging in Cancer & Vascular Disease Diagnostics Product Leadership of the Year Award
http://medgadget.com/archives/2005/03/the_bioscanir_s.html
OmniCorder Technologies Installs BioScanIR System at Leading German Cancer Center
http://findarticles.com/p/articles/mi_m0EIN/is_2004_Feb_18/ai_113374281
STAR WARS MEDICINE, ON EARTH
Venture capitalists and corporate
investors ‘sense’ OmniCorder
Technologies’ star potential at
recent Medtech Insight conference.
http://www.medtechinsight.com/advertorials/starwars.pdf
12-20-07 The following info was furnished by Mgland. He spoke directly to the TA
OS. The Transparency we embrace. Company has been very prudent here with the share structure but does have to pay the bill with things coming to fruition.
52 MILLION @ .0011 GIVES A MKT CAP OF $57,200.
OS by date (2007)
On 5/30 it was 38 million
on 6/22 39 million
7/10 40 million
9/25 unchanged
11/23 unchanged
11/30 42 million
12/19 52 million
(2009)
2/26 58 million (confirmed by FatFinger6)
It ran from pennies to $9 in 2004
Advanced BioPhotonics, Inc., a development stage company, engages in the development and commercialization of digital imaging technology for the diagnosis and management of various diseases, including cancer and vascular diseases in the United States. Its principal product includes BioScanIR system, which detects diseases that affect the perfusion or reperfusion of blood in tissues and organs. The BioScanIR system assists physicians and researchers in differentiating between normal and abnormal tissues by detecting small changes in perfusion. Advanced BioPhotonics, formerly known as OmniCorder Technologies, Inc., was founded in 1997 and changed its name to Advanced BioPhotonics, Inc. in 2005. The company is headquartered in Bohemia, New York.
Planned Clinical Trials in 2007.
· Pigmented Lesions of the Skin assessment (Melanoma). Melanoma detection and assessment represents a large clinical problem and a disease state where the BioScanIR® system may readily measure and assess the primary photonic emissions of skin tumors. In July 2007, we began a pilot research trial at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School. The first results for this trial are anticipated to be available in late November 2007. ·
Adjunctive screening and detection of breast cancer. The use of the BioScanIR® system as an adjunctive technique in breast cancer detection in certain age categories still holds great promise. This application may be particularly useful in younger women (under 50 years of age) with dense breasts who are at increased risk for breast cancer. We will continue to support the current work being done at the State University of New York Stony Brook in this area. First results should be available in late 2007.
We intend to concentrate our efforts and pursue clinical trials in the above noted applications provided that we have sufficient funds to do so. Previously, we had reported that we had also intended to organize a clinical trial to test the assessment of peripheral perfusion. The assessment of peripheral perfusion after tourniquet stress is a non invasive method of measuring peripheral outflow as a measure of systemic vascular disease. The current methods employ ultrasound techniques over which we may have significant benefits. After further investigation, we have decided to focus our limited assets on pigmented lesions of the skin assessment (Melanoma) and adjunctive screening and detection of breast cancer. As of November 1, 2007, we had two fully functional prototype or commercial units installed in various U.S. medical institutions for testing and evaluation.
Gallery View 4: (Full Sto, MACD, Aroon8)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |